April 1, 2025 06:52 AM EDTUpdated 03:23 PM

Lilly claims Phase 2 win for siRNA approach to mixed dyslipidemia

Ayisha Sharma

News Reporter

Eli Lilly’s RNA candidate has reduced levels of a protein linked with cardiovascular disease risk in a mid-stage trial in patients with high cholesterol. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lilly claims Phase 2 win for siRNA approach to mixed dyslipidemia

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Atsena gets Bain's support in $150M Series C to thwart blindness with gene therapy

Arie Belldegrun nabs two leaders for Vida Ventures amid plans for fourth fund

New CDMO emerges, acquires cell and gene manufacturer Landmark Bio

Firings sweep across FDA as former leaders lament the gutting of drug agency

Edgewise's heart drug shows promise in Phase 2 trial

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

Lil­ly claims Phase 2 win for siR­NA ap­proach to mixed dys­lipi­demia

News Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Lilly claims Phase 2 win for siRNA approach to mixed dyslipidemia